Check out some thoughts from our co-founder and CEO, highlighting the future of CAR-T for Glioblastoma and the discussion around ex vivo therapies as in vivo products hit the clinic this fall.
CEO + Co-Founder at KiraGen Bio || MS/MBA-Biotech at Harvard Business School || Termeer Fellow || Blavatnik Fellow
A great article featuring Carl June, the Father of CAR-T, was just published. It highlights his optimism for CAR-T therapies targeting Glioblastoma (our lead indication at KiraGen Bio) and reinforces his confidence in the future of ex vivo cell therapies. There's been much discussion lately about the emergence of in vivo therapies soon to enter the clinic, and how they'll coexist with ex vivo approaches. June, like us at KiraGen, believes both will play important roles for the foreseeable future. Ex vivo editing likely will always have some key advantages: -Larger payloads -No off-target cell toxicity concerns -Lower efficacy burden The technology for both approaches evolves in tandem. As in vivo editing improves, ex vivo products will likewise evolve to harbor more complex circuits and even higher multiplex edits. The result? Two distinct classes of cell therapies, each with its own pros and cons, providing oncologists with a diverse toolkit to combat cancer. At KiraGen, we're excited to be at the forefront of ex vivo innovation, pushing the boundaries of what's possible in cell therapy. Stay tuned for updates as we build upon such exciting recent clinical success for patients in need! (Credit for thoughts above: Jacob Kimmel and Dr. Shelby) https://lnkd.in/eKhEGr32